Interstage mortality among infants with hypoplastic left heart syndrome: Outcomes of a multicenter home monitoring program

Meakins, Leanne; Knox, Patty; Legge, Lea; Penner, Marie; Wiebe, Pam; Mackie, Andrew S.

doi:10.1016/j.ppedcard.2022.101610

Cited by 1 publication

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Institution of an IHM for infants with HLHS may be beneficial for reducing interstage mortality. 106 Data from the National Pediatric Cardiology Quality Improvement Collaborative have indicated a >40% reduction in interstage 1 mortality, reducing mortality to <2%, in the current era, after changes in practice such as institution of IHM. 107 According to a single-center retrospective study, institution of an IHM, compared with a historical control, was associated with an average 29% lower predicted probability of interstage death (adjusted probability, −0.29 [95% CI, −0.52 to −0.57]; P= 0.015).…”

Section: Congenital Cardiovascular Defects and Kawasaki Diseasementioning

confidence: 99%

2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

Martin,

Aday,

Almarzooq

et al. 2024

Circulation

216

View full text Add to dashboard Cite

BACKGROUND: The American Heart Association (AHA), in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, nutrition, sleep, and obesity) and health factors (cholesterol, blood pressure, glucose control, and metabolic syndrome) that contribute to cardiovascular health. The AHA Heart Disease and Stroke Statistical Update presents the latest data on a range of major clinical heart and circulatory disease conditions (including stroke, brain health, complications of pregnancy, kidney disease, congenital heart disease, rhythm disorders, sudden cardiac arrest, subclinical atherosclerosis, coronary heart disease, cardiomyopathy, heart failure, valvular disease, venous thromboembolism, and peripheral artery disease) and the associated outcomes (including quality of care, procedures, and economic costs). METHODS: The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing. The 2024 AHA Statistical Update is the product of a full year’s worth of effort in 2023 by dedicated volunteer clinicians and scientists, committed government professionals, and AHA staff members. The AHA strives to further understand and help heal health problems inflicted by structural racism, a public health crisis that can significantly damage physical and mental health and perpetuate disparities in access to health care, education, income, housing, and several other factors vital to healthy lives. This year’s edition includes additional global data, as well as data on the monitoring and benefits of cardiovascular health in the population, with an enhanced focus on health equity across several key domains. RESULTS: Each of the chapters in the Statistical Update focuses on a different topic related to heart disease and stroke statistics. CONCLUSIONS: The Statistical Update represents a critical resource for the lay public, policymakers, media professionals, clinicians, health care administrators, researchers, health advocates, and others seeking the best available data on these factors and conditions.

show abstract

Section: Congenital Cardiovascular Defects and Kawasaki Diseasementioning

confidence: 99%